HD-DXM or Thrombopoietin receptor agonists (TPO-RAs) therapy shift the FcγR balance towards inhibitory FcγRIIb in the monocytes of patients with ITP (18, 19). This evidence concerns the gene FCGR2A and autoimmune thrombocytopenic purpura.